Neurogene Inc. Common Stock (NGNE)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Neurogene as a clinical-stage science project, not a business with a durable moat. It has two gene-therapy candidates in Phase 1/2 trials: NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. That may be worth something if the data succeed, but there is no commercial product and no reliable revenue. In fiscal 2024, the year ended 2024-12-31, it reported revenue of $925,000 and a net loss of $75.1M, or EPS of -$4.28. In fiscal 2025, the year ended 2025-12-31, revenue was not available and the net loss widened to $90.4M, with EPS of -$4.24. The most recent filed quarter, fiscal Q2 2026 ended 2026-06-30, showed a net loss of $34.5M and EPS of -$1.53, much worse than fiscal Q2 2025, when the quarter ended 2025-06-30 produced a net loss of $22.0M and EPS of -$1.05. Cash burn is the central fact: trailing free cash flow was -$87.7M, a -20.3% FCF yield on the $431.4M market cap at the 2026-10-13 close. The balance sheet shows low debt, with D/E of 0.04 and an Altman Z-score of 8.13, but the Piotroski F-score is 1/9 and ROE is -45.31%, so the accounting engine is weak. FairStock's score is 32/100. At the 2026-10-13 close, FairStock calculated P/E of -4.28 and P/B of 1.57; with losses in each of the last four years, the Lynch category is none. Beta of 1.96 warns that Mr. Market will swing this widely. Without earnings or margin of safety, I would demand a much larger discount or clear clinical proof before calling it cheap.

In plain English: Neurogene is a clinical-stage biotech that is trying to develop gene medicines for rare brain diseases. It has no product on the market and has been losing money each year, so the business looks weak financially. The stock price is not supported by current profits; it mostly reflects hopes for its experimental treatments.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer